Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer.

被引：0
|
作者：
Assoun, Sandra
Campedel, Luca
Roupret, Morgan
Vaessen, Christophe
Parra, Jerome
Boostandoost, Haide Angele
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.e581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e581
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    Noonan, K. L.
    North, S.
    Bitting, R. L.
    Armstrong, A. J.
    Ellard, S. L.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1802 - 1807
  • [42] Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De laere, Brain
    Van Oyen, Peter
    Ghysel, Christophe
    Ost, Piet
    Demey, Wim
    Hoekx, Lucien
    Schrijvers, Dirk L.
    Brouwers, Barbara Anna Henk
    Lybaert, Willem
    Everaert, Els Grieta
    Ampe, Jozef
    Van Kerckhove, Piet
    De Maeseneer, Daan Joost
    Strijbos, Michiel Hendrik
    Bols, Alain
    Fransis, Karen
    Van den Eynden, Gert
    Vandebroek, Jean
    Van Laere, Steven J.
    Dirix, Luc Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [44] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [45] Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
    Pal, Sumanta Kumar
    Patel, Jaymala
    He, Miaoling
    Foulk, Brad
    Kraft, Katherine
    Smirnov, Denis A.
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Bhargava, Vipul
    Jones, Jeremy O.
    CANCER, 2018, 124 (06) : 1216 - 1224
  • [46] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
  • [47] Optimal Sequencing of Docetaxel and Abiraterone in Men With Metastatic Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    Xhou, Xian C.
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael T.
    Antonarakis, Emmanuel S.
    PROSTATE, 2015, 75 (15): : 1814 - 1820
  • [48] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [49] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [50] Response to Enzalutamide in patients with metastatic Castration-resistant prostate (mCRCP) cancer after chemotherapy and Abiraterone treatment
    Stroelin, P.
    Tennstedt, P.
    Steuber, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 87 - 87
12345